We investigated sirolimus and mycophenolate mofetil (MMF) as GVHD prophylaxis in patients with advanced hematological malignancies receiving myeloablative hematopoietic cell transplantation (HCT ...

Although a control group was not included, the risks of grade II to IV and grade III or IV acute GVHD were substantially lower than previously observed with sirolimus plus tacrolimus alone, for ...

Sirolimus-Eluting Stents Safe But Minimally Effective for in-Stent Restenosis. ... 25% vs. 6% -- and 46% had Mehran Type III-IV lesions compared with 22% of the control patients.

Sirolimus was initiated at a median of 9 (1–255) days after glucocorticoid initiation. ... In this trial, 21 patients with advanced-grade (grade III=10; grade IV=11) ...

These trials consisted of the studies TAXUS-I, TAXUS-II, TAXUS-IV, TAXUS-V, and TAXUS-VI. 5–9 These specific trials were selected because they are the only double-blind trials that compared each ...

Dosing in the trial was 100 mg/m 2 IV on days 1 and 8 of a 21-day cycle, which is the approved dosing. Median time to nab-sirolimus response was 1.4 months. AMPECT was funded by Aadi Bioscience.

SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Safety and Efficacy Measures with Both CYPHER Stent and Xience Stent BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Investigators reported ...

Patients with advanced cancer who consumed 8 oz of grapefruit juice daily more than tripled their levels of sirolimus ... equal to that achieved with a 25-mg dose of temsirolimus IV — at ...

Sirolimus vs Paclitaxel. In the parts of the world where these devices are available, ... were type II, about 25% were type I, and 15% were type III/IV. The primary endpoint was late lumen loss within ...

Monitor sirolimus blood concentrations (obtain trough level 3–4 days after a loading dose), renal function, lipids, urine protein and for viral infections (eg, BK virus-associated nephropathy).

Sirolimus may be a safe and effective alternative for patients with chronic spontaneous urticaria who do not respond to other treatments, according to a study published in The Journal of Allergy ...

HealthDay News — Sirolimus may be beneficial for patients with diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH), according to a research letter published online April 10 in ...